Original StudyDanazol (cas 17230-88-5) as First-Line Therapy for Myelodysplastic Syndrome

Add time:08/22/2019    Source:sciencedirect.com

BackgroundAllogeneic stem cell transplantation (ASCT) represents the only option with a potential cure rate of 30% to 50% in myelodysplastic syndrome (MDS); however, < 5% of patients are optimal candidates for this management. Therapeutic options are limited in patients unsuitable for ASCT. Evidence that androgens might be beneficial in MDS is controversial. We aimed to document the clinical outcomes of patients diagnosed with MDS treated with danazol as first-line therapy.

We also recommend Trading Suppliers and Manufacturers of Danazol (cas 17230-88-5). Pls Click Website Link as below: cas 17230-88-5 suppliers

Prev:Research paperMulticenter phase 2 study of combination therapy with ruxolitinib and Danazol (cas 17230-88-5) in patients with myelofibrosis
Next:Microbial transformation of Danazol (cas 17230-88-5) with Cunninghamella blakesleeana and anti-cancer activity of Danazol (cas 17230-88-5) and its transformed products)